Well, it looks like Amarin (AMRN 9.38%)investors will have to wait a little bit longer -- again -- to discover whether the FDA grants the company's hypertriglyceridemia drug Vascepa New Chemical Entity (NCE) status. The FDA updated its database of approved drugs today, and many believed that Vascepa would either be given or denied the NCE designation. This issue has kept Amarin in neutral during the past few months, and negotiations with possible partners or acquirers, such as AstraZeneca (AZN -0.80%) and Teva (TEVA 0.71%), have stalled.
In this video, health-care analysts David Williamson and Max Macaluso discuss this ongoing delay, and how it impacts Amarin's plans going forward.
